BIOCRYST PHARMACEUTICALS, INC. Restructuring Costs
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Restructuring Costs of $6.31 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2026-02-26
- BIOCRYST PHARMACEUTICALS, INC. restructuring costs for the quarter ending 2024-09-30 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. restructuring costs for the quarter ending 2024-06-30 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. restructuring costs for the quarter ending 2024-03-31 was $1.26M.
- BIOCRYST PHARMACEUTICALS, INC. restructuring costs for fiscal 2025 was $6.31M, a 399.53% increase from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. restructuring costs for fiscal 2024 was $1.26M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 9 month | Restructuring Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.31M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $1.26M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $1.26M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-11-05 | $1.26M derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2024-03-31 | $1.26M 10-Q · filed 2024-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |